Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study

Documenti analoghi

• Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor
  di: Zi‐Yang Shi, et al.
  Pubblicazione: (2024)
• Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A prospective, multicentre, phase 2 clinical trial
  di: Qi Liu, et al.
  Pubblicazione: (2025)
• A multicentre randomized open‐label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia
  di: Haoyi Wang, et al.
  Pubblicazione: (2026)
• Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
  di: Kaitlin Annunzio, et al.
  Pubblicazione: (2024)
• Optimizing Zanubrutinib Dosing in Patients: A PBPK‐BO Model Approach to Drug–Drug Interactions and Patients with Hepatic Impairment
  di: Jiawei Ren, et al.
  Pubblicazione: (2025)